{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:39:32Z","timestamp":1793943572491,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000241","name":"Physicians' Services Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006126","name":"Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07450-z","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:02:48Z","timestamp":1783746168000},"page":"4597-4607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-0646","authenticated-orcid":false,"given":"Cal H.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Gorgiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowrin","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonny H. M.","family":"Banh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneet","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlene","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetha","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithiakishna","family":"Selvathesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Wei","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanka","family":"Vasilevska-Ristovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulan S.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"7450_CR1","doi-asserted-by":"publisher","unstructured":"Veltkamp F, Rensma LR, Bouts AHM, LEARNS consortium (2021) Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148:e2020029249. https:\/\/doi.org\/10.1542\/peds.2020-029249","DOI":"10.1542\/peds.2020-029249"},{"key":"7450_CR2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"7450_CR3","doi-asserted-by":"publisher","unstructured":"Croitoru A, Balgradean M (2022) Treatment-associated side effects in patients with steroid-dependent nephrotic syndrome. Maedica (Bucur) 17:285\u2013290. https:\/\/doi.org\/10.26574\/maedica.2022.17.2.285","DOI":"10.26574\/maedica.2022.17.2.285"},{"key":"7450_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY-H Chan","year":"2023","unstructured":"Chan EY-H, Yap DY-H, Colucci M et al (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"7450_CR5","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359\u20137368. https:\/\/doi.org\/10.1038\/sj.onc.1206939","journal-title":"Oncogene"},{"key":"7450_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY-H Chan","year":"2022","unstructured":"Chan EY-H, Ma AL-T, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927\u2013931. https:\/\/doi.org\/10.1007\/s00467-021-05345-9","journal-title":"Pediatr Nephrol"},{"key":"7450_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Deng F, Wang X et al (2024) Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome. Kidney Int Rep 9:1220\u20131227. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1395","journal-title":"Kidney Int Rep"},{"key":"7450_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae348","volume":"18","author":"X Zhang","year":"2025","unstructured":"Zhang X, Jin Y, Liu F et al (2025) Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome. Clin Kidney J 18. https:\/\/doi.org\/10.1093\/ckj\/sfae348","journal-title":"Clin Kidney J"},{"key":"7450_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-25","volume":"14","author":"N Hussain","year":"2013","unstructured":"Hussain N, Zello JA, Vasilevska-Ristovska J et al (2013) The rationale and design of Insight into nephrotic syndrome: investigating genes, health and therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome. BMC Nephrol 14:25. https:\/\/doi.org\/10.1186\/1471-2369-14-25","journal-title":"BMC Nephrol"},{"key":"7450_CR10","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Gibson KL, Vivarelli M et al (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107:S241\u2013S289. https:\/\/doi.org\/10.1016\/j.kint.2024.11.007","journal-title":"Kidney Int"},{"key":"7450_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"key":"7450_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","volume":"58","author":"DA Colantonio","year":"2012","unstructured":"Colantonio DA, Kyriakopoulou L, Chan MK et al (2012) Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemicalmarkers in a healthy and multiethnic population of children. Clin Chem 58:854\u2013868. https:\/\/doi.org\/10.1373\/clinchem.2011.177741","journal-title":"Clin Chem"},{"key":"7450_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2025.110923","volume":"137","author":"M L\u00f8k","year":"2025","unstructured":"L\u00f8k M, Dandanell FE, Frithioff-B\u00f8js\u00f8e C et al (2025) Reference intervals for serum immunoglobulin A, G, and M in a Danish paediatric population-based cohort. Clin Biochem 137:110923. https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110923","journal-title":"Clin Biochem"},{"key":"7450_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3906\/sag-1807-282","volume":"49","author":"RO Bayram","year":"2019","unstructured":"Bayram RO, \u00d6zdemir H, Emsen A (2019) Reference ranges for serum immunoglobulin (IgG, IgA, and IgM) and IgG subclass levels in healthy children. Turk J Med Sci 49:497\u2013505. https:\/\/doi.org\/10.3906\/sag-1807-282","journal-title":"Turk J Med Sci"},{"key":"7450_CR15","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/ndt\/gfaf103","volume":"40","author":"IF Shatat","year":"2025","unstructured":"Shatat IF, Mostafa O, Karim K et al (2025) Rituximab-induced persistent hypogammaglobulinemia in children with nephrotic syndrome: common or rare? Nephrol Dial Transplant 40:1815\u20131819. https:\/\/doi.org\/10.1093\/ndt\/gfaf103","journal-title":"Nephrol Dial Transplant"},{"key":"7450_CR16","first-page":"634","volume":"112","author":"S Mankarious","year":"1988","unstructured":"Mankarious S, Lee M, Fischer S et al (1988) The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112:634\u2013640","journal-title":"J Lab Clin Med"},{"key":"7450_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00580","volume":"7","author":"A Saxena","year":"2016","unstructured":"Saxena A, Wu D (2016) Advances in therapeutic Fc engineering - modulation of IgG-associated effector functions and serum half-life. Front Immunol 7:580. https:\/\/doi.org\/10.3389\/fimmu.2016.00580","journal-title":"Front Immunol"},{"key":"7450_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong M-S, Farmer JR et al (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1:e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"key":"7450_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106526","volume":"11","author":"EY Chan","year":"2026","unstructured":"Chan EY, Au CT, Yu EL et al (2026) Efficacy and safety of rituximab therapy to sustain remission in young children with childhood nephrotic syndrome. Kidney Int Rep 11:106526. https:\/\/doi.org\/10.1016\/j.ekir.2026.106526","journal-title":"Kidney Int Rep"},{"key":"7450_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K et al (2022) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol 37:1057\u20131066. https:\/\/doi.org\/10.1007\/s00467-021-05304-4","journal-title":"Pediatr Nephrol"},{"key":"7450_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10157-023-02374-6","volume":"27","author":"R Ohyama","year":"2023","unstructured":"Ohyama R, Fujinaga S, Sakuraya K et al (2023) Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study. Clin Exp Nephrol 27:865\u2013872. https:\/\/doi.org\/10.1007\/s10157-023-02374-6","journal-title":"Clin Exp Nephrol"},{"key":"7450_CR22","doi-asserted-by":"publisher","first-page":"AB29","DOI":"10.1016\/j.jaci.2024.12.097","volume":"155","author":"J Chung","year":"2025","unstructured":"Chung J, Chung Z, Yu A et al (2025) Rituximab-induced hypogammaglobinemia in children with nephrotic syndrome: a systematic review and meta-analysis. J Allergy Clin Immunol 155:AB29. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.097","journal-title":"J Allergy Clin Immunol"},{"key":"7450_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.12998\/wjcc.v7.i9.1021","volume":"7","author":"P Marzuillo","year":"2019","unstructured":"Marzuillo P, Guarino S, Esposito T et al (2019) Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values. World J Clin Cases 7:1021\u20131027. https:\/\/doi.org\/10.12998\/wjcc.v7.i9.1021","journal-title":"World J Clin Cases"},{"key":"7450_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2020","unstructured":"Parmentier C, Delbet J-D, Decramer S et al (2020) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:455\u2013462. https:\/\/doi.org\/10.1007\/s00467-019-04398-1","journal-title":"Pediatr Nephrol"},{"key":"7450_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","volume":"24","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Tomii Y (2020) Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol 24:386\u2013387. https:\/\/doi.org\/10.1007\/s10157-020-01858-z","journal-title":"Clin Exp Nephrol"},{"key":"7450_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-012-2361-z","volume":"28","author":"L Delbe-Bertin","year":"2013","unstructured":"Delbe-Bertin L, Aoun B, Tudorache E et al (2013) Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol 28:447\u2013451. https:\/\/doi.org\/10.1007\/s00467-012-2361-z","journal-title":"Pediatr Nephrol"},{"key":"7450_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/cn108835","volume":"85","author":"S Fujinaga","year":"2016","unstructured":"Fujinaga S, Ozawa K, Sakuraya K et al (2016) Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol 85:340\u2013345. https:\/\/doi.org\/10.5414\/cn108835","journal-title":"Clin Nephrol"},{"key":"7450_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J et al (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653. https:\/\/doi.org\/10.3389\/fimmu.2019.01653","journal-title":"Front Immunol"},{"key":"7450_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ndt\/gfac228","volume":"38","author":"A Sinha","year":"2023","unstructured":"Sinha A, Mathew G, Arushi A et al (2023) Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. Nephrol Dial Transplant 38:939\u2013949. https:\/\/doi.org\/10.1093\/ndt\/gfac228","journal-title":"Nephrol Dial Transplant"},{"key":"7450_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","volume":"377","author":"V Mears","year":"2023","unstructured":"Mears V, Jakubecz C, Seeco C et al (2023) Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. J Neuroimmunol 377:578066. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578066","journal-title":"J Neuroimmunol"},{"key":"7450_CR31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","volume":"41","author":"SD Wade","year":"2021","unstructured":"Wade SD, Kyttaris VC (2021) Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatol Int 41:1115\u20131124. https:\/\/doi.org\/10.1007\/s00296-021-04847-x","journal-title":"Rheumatol Int"},{"key":"7450_CR32","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/0961203313507990","volume":"22","author":"E Lim","year":"2013","unstructured":"Lim E, Tao Y, White AJ et al (2013) Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus 22:1382\u20131387. https:\/\/doi.org\/10.1177\/0961203313507990","journal-title":"Lupus"},{"key":"7450_CR33","first-page":"179","volume":"52","author":"SE Maddison","year":"1975","unstructured":"Maddison SE, Stewart CC, Farshy CE, Reimer CB (1975) The relationship of race, sex, and age to concentrations of serum immunoglobulins expressed in international units in healthy adults in the USA. Bull World Health Organ 52:179\u2013185","journal-title":"Bull World Health Organ"},{"key":"7450_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcla.1860090107","volume":"9","author":"DJ Tollerud","year":"1995","unstructured":"Tollerud DJ, Brown LM, Blattner WA et al (1995) Racial differences in serum immunoglobulin levels: relationship to cigarette smoking, T-cell subsets, and soluble interleukin-2 receptors. J Clin Lab Anal 9:37\u201341. https:\/\/doi.org\/10.1002\/jcla.1860090107","journal-title":"J Clin Lab Anal"},{"key":"7450_CR35","doi-asserted-by":"publisher","first-page":"AB85","DOI":"10.1016\/j.jaci.2011.12.643","volume":"129","author":"A Mehta","year":"2012","unstructured":"Mehta A, Ramirez G, Ye G et al (2012) Correlation between IgG, IgA, IgM and BMI or race in a large pediatric population. J Allergy Clin Immunol 129:AB85. https:\/\/doi.org\/10.1016\/j.jaci.2011.12.643","journal-title":"J Allergy Clin Immunol"},{"key":"7450_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anai.2020.03.018","volume":"125","author":"T Harkness","year":"2020","unstructured":"Harkness T, Fu X, Zhang Y et al (2020) Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. Ann Allergy Asthma Immunol 125:190-195.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.03.018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"7450_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K et al (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4:e2036321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36321","journal-title":"JAMA Netw Open"},{"key":"7450_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v120.21.4888.4888","volume":"120","author":"E Shabad","year":"2012","unstructured":"Shabad E, Mangoubi E, Valkovsky O et al (2012) Delayed onset adverse effects associated with rituximab treatment in patients with non-Hodgkin\u2019s lymphoma \u2013 a single center experience. Blood 120:4888. https:\/\/doi.org\/10.1182\/blood.v120.21.4888.4888","journal-title":"Blood"},{"key":"7450_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00467-023-06124-4","volume":"39","author":"N Choi","year":"2024","unstructured":"Choi N, Min J, Kim JH et al (2024) Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome. Pediatr Nephrol 39:771\u2013780. https:\/\/doi.org\/10.1007\/s00467-023-06124-4","journal-title":"Pediatr Nephrol"},{"key":"7450_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.kint.2023.06.013","volume":"104","author":"M Colucci","year":"2023","unstructured":"Colucci M, Angeletti A, Zotta F et al (2023) Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome. Kidney Int 104:577\u2013586. https:\/\/doi.org\/10.1016\/j.kint.2023.06.013","journal-title":"Kidney Int"},{"key":"7450_CR41","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S et al (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822. https:\/\/doi.org\/10.1681\/ASN.2015050523","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07450-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07450-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07450-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:16Z","timestamp":1792104856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07450-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7450"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07450-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analysis and interpretation of data, writing of the report, or the decision to submit for publication.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}